HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $7.5 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Akebia Therapeutics, maintaining a price target of $7.5.
October 23, 2024 | 11:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating for Akebia Therapeutics, maintaining a price target of $7.5.
The reiteration of a Buy rating and maintenance of a $7.5 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in Akebia Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100